Novartis is scolded by U.K. trade group for the third time this year over Entresto marketing
For the third time this year, Novartis has been rebuked by a U.K. trade group for misleading promotional efforts for its biggest-selling drug.
Related Articles
NIH postdocs will get a raise next year — but not as much as they hoped
The NIH will raise the minimum salary for postdocs to $61,008, responding to calls from young life scientists to provide a living wage.
Health care lobbying giants spent big as little got done in Congress
Congress did nothing this spring to rein in how pharmacy benefit managers operate, and the PBM industry spent big to get that result, new disclosures…
Day One drug for common childhood brain tumor approved by FDA
Researchers hope the pill, which will be marketed as Ojemda, may allow more patients to reach adulthood without highly toxic treatments such as radiation.
Telehealth startups see an opportunity in long-ignored, complex chronic diseases
Easily a decade can pass before someone with a complex chronic condition gets a proper diagnosis. New telehealth companies aim to shorten that time and…
Trump surrogates hint at how he could reshape U.S. health care policy
Donald Trump’s health care priorities remain fuzzy. But one thing is certain: A second Trump administration would put its own stamp on a host of…
Accreditation agencies take on telehealth with new virtual care standards
The Joint Commission and the National Committee for Quality Assurance will launch updated accreditation programs for telehealth providers.
Use evidence to support early coverage of gene therapy after accelerated approval
Gene therapies represent an evidence problem. Because they are just beginning to be used, little long-term data exists on their effectiveness and downstream risks.
In a scientific first, researchers use CRISPR base editing to treat liver disease in fetal monkeys
In a scientific first, researchers have used CRISPR base editing to treat liver disease in fetal monkeys.
Biden administration finalizes abortion privacy protections
HHS released a final rule that would put abortion services under the same federal privacy protections as other health care data covered by HIPAA.
How a scientific slip-up caused a pregnant woman to get an untested treatment for preterm birth
Confusion over Makena, a controversial failed preterm delivery drug, caused some pregnant women to receive an untested treatment.